<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2013-721-4</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-1686</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Применение ингибиторов фактора  некроза опухоли α при идиопатическом панникулите Вебера–Крисчена</article-title><trans-title-group xml:lang="en"><trans-title>THE USE OF TUMOR NECROSIS FACTOR α INHIBITORS IN PATIENTS WITH WEBER-CHRISTIAN DISEASE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Egorova</surname><given-names>Olga Nikolayevna</given-names></name></name-alternatives><email xlink:type="simple">onegorova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Belov</surname><given-names>B S</given-names></name></name-alternatives><email xlink:type="simple">onegorova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>RadenskaLopovok</surname><given-names>S G</given-names></name></name-alternatives><email xlink:type="simple">onegorova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Pushkova</surname><given-names>O V</given-names></name></name-alternatives><email xlink:type="simple">onegorova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Savushkina</surname><given-names>N M</given-names></name></name-alternatives><email xlink:type="simple">onegorova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Khrennikov</surname><given-names>Ya B</given-names></name></name-alternatives><email xlink:type="simple">onegorova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E L</given-names></name></name-alternatives><email xlink:type="simple">onegorova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Научно-исследовательский&#13;
институт ревматологии им. В.А. Насоновой» РАМН, Москва, Россия</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Nasonova Research Institute of Rheumatology, Russian Academy of Medical&#13;
Sciences, Moscow, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>15</day><month>01</month><year>2014</year></pub-date><volume>51</volume><issue>6</issue><fpage>721</fpage><lpage>4</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Egorova O.N., Belov B.S., RadenskaLopovok S.G., Pushkova O.V., Savushkina N.M., Khrennikov Y.B., Nasonov E.L., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Egorova O.N., Belov B.S., RadenskaLopovok S.G., Pushkova O.V., Savushkina N.M., Khrennikov Y.B., Nasonov E.L.</copyright-holder><copyright-holder xml:lang="en">Egorova O.N., Belov B.S., RadenskaLopovok S.G., Pushkova O.V., Savushkina N.M., Khrennikov Y.B., Nasonov E.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/1686">https://rsp.mediar-press.net/rsp/article/view/1686</self-uri><abstract><p>Идиопатический панникулит Вебера–Крисчена (ИПВК) относится к редким заболеваниям из группы диффузных болезней соединительной ткани. Лечение ИПВК не разработано и проводится, как правило, эмпирически. В статье представлено первое описание применения ингибиторов фактора некроза опухоли α у больной с инфильтративной формой ИПВК, проанализирована тактика ведения этой категории пациентов.</p></abstract><trans-abstract xml:lang="en"><p>Weber-Christian disease (WCD), also known as idiopathic lobular panniculitis, is a rare disease belonging to the group of diffuse connective tissue diseases. No therapy for WCD has been developed; empirical treatment is typically used. The first description of the use of tumor necrosis factor α inhibitors in a female patient with infiltrative WCD is presented. The tactics of managing this patient category are analyzed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>идиопатический панникулит Вебера–Крисчена</kwd><kwd>этанерцепт</kwd><kwd>адалимумаб</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Weber-Christian disease</kwd><kwd>idiopathic lobular panniculitis</kwd><kwd>etanercept</kwd><kwd>adalimumab</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
